<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692234</url>
  </required_header>
  <id_info>
    <org_study_id>Homoarginine in Stroke</org_study_id>
    <nct_id>NCT03692234</nct_id>
  </id_info>
  <brief_title>Homoarginine Supplementation in Patients After Stroke</brief_title>
  <acronym>HiS</acronym>
  <official_title>Homoarginine in Stroke (HiS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study represents a follow-up of the previous study &quot;Single and Multiple Doses of an Oral
      Formulation of L-Homoarginine in Healthy Human Subjects&quot; (NCT02675660). This study will
      evaluate the applicability of an oral formulation of L-homoarginine to normalize homoarginine
      blood levels in patients with acute ischemic stroke.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized double-blind placebo controlled</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Homoarginine serum concentration</measure>
    <time_frame>six month</time_frame>
    <description>Normalization of homoarginine serum concentration to levels &gt;2.1 umol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intima-media thickness</measure>
    <time_frame>six month</time_frame>
    <description>Intima-media thickness (IMT) measured at both common carotid arteries using an edge detection system. Plaques are defined as protrusion of ≥1.5 mm in common, internal and external carotid artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale</measure>
    <time_frame>six month</time_frame>
    <description>National Institute of Health Stroke Scale (NIHSS) will be assessed by a neurologist. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 (normal) and 4 (maximum impairment). The maximum possible score is 42, with the minimum score being a 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ranking Scale</measure>
    <time_frame>six month</time_frame>
    <description>Modified Ranking Scale (mRS) is a scale for measuring the degree of disability of a stroke patients. The scale runs from 0 (perfect health) to 6 (death).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Deficiency; Diet</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules containing lactose - oral once weekly administration for six month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>homoarginine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>125 mg L-homoarginine supplement - oral once weekly administration for six month</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>125 mg L-homoarginine</intervention_name>
    <description>capsules for oral supplementation</description>
    <arm_group_label>homoarginine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>capsules for oral supplementation</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ischemic stroke (CT or MRI), high-risk transient ischemic attack (ABCD2-score &gt;= 4) or
             acute central retinal artery occlusion

          -  serum homoarginine &lt;/= 2.1 umol/L

          -  signed informed consent

        Exclusion Criteria:

          -  no acute stroke

          -  serum homoarginine &gt; 2.1 umol/L

          -  heart failure (NYHA &gt; 1)

          -  chronic kidney disease (GFR &lt;60 mL/min)

          -  not competent

          -  pregnancy, lactation

          -  no or withdrawn signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chi-un Choe, MD</last_name>
    <phone>+49407410</phone>
    <phone_ext>22389</phone_ext>
    <email>cchoe@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Edzard Schwedhelm, PhD</last_name>
    <phone>+49407410</phone>
    <phone_ext>54891</phone_ext>
    <email>schwedhelm@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-un Che, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Atzler D, Schönhoff M, Cordts K, Ortland I, Hoppe J, Hummel FC, Gerloff C, Jaehde U, Jagodzinski A, Böger RH, Choe CU, Schwedhelm E. Oral supplementation with L-homoarginine in young volunteers. Br J Clin Pharmacol. 2016 Dec;82(6):1477-1485. doi: 10.1111/bcp.13068. Epub 2016 Sep 20.</citation>
    <PMID>27434056</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>homoarginine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

